Prolong Pharmaceuticals’ Flagship Product SANGUINATE™ Granted Orphan Drug Designation by the FDA

Industry News

Prolong Pharmaceuticals, headquartered in South Plainfield, NJ announced that the FDA has granted Orphan Drug Designation for its SANGUINATETM for the treatment of Sickle Cell Disease (SCD).  SCD is a group of rare genetic disorders that affects blood hemoglobin oxygen delivery function, which can lead to organ damage and multiple comorbidities.  A particularly serious complication of SCD is pulmonary hypertension.  Currently, there is no cure for SCD and its complications are managed by symptom alleviation.  SANGUINATETM is an investigational drug candidate with anti-vaso-constrictive properties that facilitates oxygen delivery to oxygen-deprived tissues and organs.  It is under evaluation in a Phase II trial for the reduction or prevention of delayed cerebral ischemia following subarachnoid hemorrhage.  It is also being evaluated for the treatment of beta-thalassemia.

Dr. Abraham Abuchowski, Prolong Pharmaceuticals’ founder/CEO/SCO is considered the father of PEGylation technology, now the most widely used protein drug delivery system.


Original Article:

Subscribe to WXPress

Receive our newsletter and information on upcoming events.